EFFECT OF INCLISIRAN ON LDL-C REDUCTION ACROSS DIFFERENT BACKGROUND LIPID LOWERING TREATMENTS: ANALYSES FROM ORION-11

Authors :: David Kallend
Frederick Raal
Peter Wijngaard
John J.P. Kastelein
Kausik K. Ray
Wolfgang Koenig
Scott Wright
Lawrence Leiter
Source :: Journal of the American College of Cardiology. 75:2078
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.
Abstract: Lipid lowering therapies (LLT) increase PCSK9. Inclisiran reduces hepatic PCSK9 synthesis and LDL-C. The effect of inclisiran on LDL-C by background LLT status is unknown. ORION-11 randomized 1617 subjects with stable ASCVD or ASCVD-risk equivalent and elevated LDL-C despite maximum tolerated

Subjects :: 03 medical and health sciences
0302 clinical medicine
Inclisiran
business.industry
PCSK9
Medicine
lipids (amino acids, peptides, and proteins)
030212 general & internal medicine
Lipid lowering
030204 cardiovascular system & hematology
Pharmacology
Cardiology and Cardiovascular Medicine
business

Full Text Access

Tools